Skip to content

Veteran Centered Meal Intervention in Chronic Kidney Disease

A Veteran-Centered Medically Tailored Meal Intervention to Improve Clinical and Patient Reported Outcomes in Chronic Kidney Disease (VETCKD)

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07793591
Acronym
VETCKD
Enrollment
100
Registered
2026-08-28
Start date
2027-10-01
Completion date
2030-08-31
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

medically tailored meals, chronic kidney disease, hypertension, nutrition, diet, Veterans

Brief summary

This study will study if medically tailored meals can improve health and well-being among Veterans with kidney disease. Participants will be randomly assigned to receive either medically tailored meals or usual care (wait-list control) for 3 months, followed by follow-up/crossover period. The study will evaluate blood pressure, kidney health, diet, quality of life, and other health outcomes, as well as the feasibility and acceptability of providing medically tailored meals to Veterans with kidney disease.

Detailed description

This pilot randomized clinical trial will evaluate the feasibility, acceptability, and preliminary effects of medically tailored meals among Veterans with chronic kidney disease. Approximately 100 Veterans with stage 3b or 4 chronic kidney disease and elevated systolic blood pressure will be enrolled and randomized 1:1 to receive medically tailored meals or usual care during an initial 3-month intervention period. Participants initially assigned to usual care will subsequently receive medically tailored meals during a 3-month crossover period. All participants will be followed for 6 months. The medically tailored meal intervention will provide prepared meals designed to support dietary recommendations for chronic kidney disease and cardiovascular health. The study will assess intervention feasibility and acceptability, including recruitment, adherence, retention, completion of study assessments, and participant experiences with the meals. Clinical outcomes will include systolic blood pressure, kidney function and injury measures, cardiometabolic laboratory markers, and vascular function. Dietary intake and diet quality will be assessed using 24-hour dietary recalls. Patient-reported and behavioral outcomes will include kidney disease-related quality of life, general health and well-being, treatment burden, and measures related to dietary behavior and self-management. Healthcare utilization and medication use will also be evaluated. Assessments will generally occur at baseline, 3 months, and 6 months.

Interventions

Medically tailored meals are prepared to support dietary recommendations for chronic kidney disease and cardiovascular health while considering individual dietary needs and preferences. The intervention also included nutrition education and study-related dietary support.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Clinical outcome assessments will be conducted by study personnel who are masked to participant treatment assignment when feasible. Participants and intervention personnel will not be masked due to the nature of the dietary intervention.

Intervention model description

Participants will be randomized 1:1 to the medically tailored meal intervention or wait-list control group and followed in parallel.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Veteran enrolled in the Veterans Health Administration * Stage 3b or stage 4 Chronic Kidney Disease (CKD) ((estimated glomerular filtration rate (eGFR) 15-44 milliliter (mL)/minute/1.73 square meter (m²)) * Systolic blood pressure 140-160 mmHg (millimeters of mercury); with a ± 5 mmHg tolerance range * Body mass index (BMI) between 18.5 and 40.0 kilogram (kg)/square meter (m²) * Able and willing to provide informed consent * Able and willing to participate in study visits and study procedures * Able to receive medically tailored meal deliveries within the study service area

Exclusion criteria

* Inability to communicate in English or severe hearing impairment either, preventing study participation * Participation in a medically tailored meal program within the previous 6 months * Diagnosis of heart failure * Major active gastrointestinal disorder that would interfere with participation or nutritional management * Active cancer treatment (chemotherapy) or anticipated treatment within the next 12 months * Pregnancy * Current homelessness preventing meal delivery * Active substance use disorder not in remission * Active psychosis or another condition that would impair participation * Terminal illness or life expectancy less than 12 months * Any other medical, psychiatric, or social condition that, in the opinion of the investigators, would make participation unsafe or interfere with completion of the study

Design outcomes

Primary

MeasureTime frameDescription
Systolic blood pressure (SBP)3 monthsChange in systolic blood pressure (SBP), measured in mmHg, from baseline to the 3-month assessment.

Secondary

MeasureTime frameDescription
Urine albumin-to-creatinine ratio (UACR)3 monthsChange in urine albumin-to-creatinine ratio (UACR; milligrams/gram) from baseline to 3 months, measured using urine laboratory testing through the VA clinical laboratory.
Estimated glomerular filtration rate (eGFR)3 monthsChange in estimated glomerular filtration rate (eGFR; milliliter/minute/1.73\^square meter) from baseline to 3 months, based on serum creatinine OR cystatin C, measured through the VA clinical laboratory.

Countries

United States

Contacts

CONTACTLuis M Perez, PhD RD
luis.perez2@va.gov(720) 467-0757
CONTACTMaryam I Nuriyeva, MPH
Maryam.Nuriyeva@va.gov(720) 857-2712
PRINCIPAL_INVESTIGATORLuis M Perez, PhD RD

Rocky Mountain Regional VA Medical Center, Aurora, CO

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026